Adrenocortical cancer treatment

Area of Science:

• Oncology
• Endocrinology
• Rare Cancers

Background:

• Adrenocortical cancer (ACC) is a rare endocrine malignancy with a poor prognosis.
• It affects individuals in early childhood and middle age, with a higher incidence in females.
• Symptoms include hormonal imbalances like Cushing syndrome, virilization, hypertension, or abdominal obstruction.

Purpose of the Study:

• To summarize the current understanding of adrenocortical cancer (ACC) epidemiology, clinical presentation, and treatment outcomes.
• To highlight the limitations of existing therapies and the need for novel treatment approaches.

Main Methods:

• Review of existing literature on adrenocortical cancer (ACC).
• Analysis of common molecular alterations in sporadic ACC, including IGF-II overexpression and TP53 mutations.
• Evaluation of current chemotherapy regimens and their efficacy.

Main Results:

• Standard chemotherapy regimens (etoposide, doxorubicin, cisplatin, mitotane, streptozotocin) show disappointing overall survival rates.
• Hormonal evaluation is critical for diagnosis and prognosis assessment.
• Established genetic abnormalities are noted in familial and congenital forms of ACC.

Conclusions:

• Hormonal evaluation is essential for diagnosing adrenocortical cancer (ACC).
• Prognosis is influenced by various factors, and current treatments yield limited survival benefits.
• Emerging therapies targeting IGF-I receptor, tyrosine kinases, and angiogenesis are under investigation for improved outcomes.